Form 4: Akero Therapeutics COO Jonathan Young Sells Shares Under 10b5-1 Trading Plan

Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold shares of common stock on September 3, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Jonathan Young, the Chief Operating Officer of Akero Therapeutics, sold shares of the company's common stock on September 3, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 27, 2023.
• A total of 3,710 shares were sold at a weighted average price of $26.419, with individual prices ranging from $26.080 to $27.010.
• An additional 1,290 shares were sold at a weighted average price of $27.576, with individual prices ranging from $27.105 to $28.090.
• Following these transactions, Young directly owns 236,854 shares of Akero Therapeutics common stock.
• Young also has indirect ownership of 20,000 shares held in each of three irrevocable trusts for the benefit of his children.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to insider trading. The sentiment is neutral as it simply reports transactions.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on any specific non-public information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider information.

Key Dates